|
Re: not good news
Debbie,
I absolutely agree in terms of potential benefits of a more metronomic, more frequent lower dose strategy. I mention that in the post. That seems especially worthy of consideration with Tykerb in the mix. I just meant that based on numerous postings on various boards, patients often don't get advice on how to manage the side effects...just have their dose reduced when they occur, which often means stopping altogether for a bit. If it's a conscious decision to pursue a schedule for efficacy, that's one thing. If they're needlessly altering the schedule when some relatively simple side effect controls can be used, that seems lame.
In my mom's case, I brought information on how to deal with the side effects thinking the NP would be all over them. She quickly glanced at it, said "Oh, this looks good" and handed it back.
To me, another example of pharma only mindset.
But Pam, it seems encouraging that your onc is going full bore on multiple pathways.
Have you brought up the issue of chemosensitivity testing?
|
Threaded Mode